In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeoGenesis Pharmaceuticals Inc.

Division of Merck & Co. Inc.

Latest From NeoGenesis Pharmaceuticals Inc.

Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.
BioPharmaceutical Strategy

The Buzz at JP Morgan--Biopharma: New Models Wanted

Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.
BioPharmaceutical Strategy

The Better Exit for Private Biotechs: M&A

Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.
Business Strategies

Amgen Moves Beyond Proteins

Amgen's revenue stream depends largely on just two molecules. It has spent loads of money on the search for replacements, but as yet has relatively little to show for it--at least, little that's been visible to those outside the company. To enlarge its opportunity set, Amgen is moving beyond its macromolecule-only heritage. A fresh cadre of executives, many from Merck, aim to add small-molecule capabilities and leverage corporate understanding of proteins and pathway biology. Amgen is also tapping into a host of other organizations whose technologies, targets, assays and very ways of thinking promise to make the firm more competitive than it could be on its own. While some investors think Amgen is making all the right moves, others are still concerned about the company's ability to bring enough new drugs to market, fast enough, to fill in behind its blockbuster proteins.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • NeoGenesis Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Henry B Skinner, PhD, Pres. & CEO
    David Hunter, VP, Fin. & CFO
    Steven Adams, PhD, SVP, Corp. Dev. & CSO
  • Contact Info
  • NeoGenesis Pharmaceuticals Inc.
    Phone: (617) 868-1500
    840 Memorial Dr., 5th Fl.
    Cambridge, MA 02139